Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and ...

In a move expected to benefit thousands of New Jersey residents living with obesity and type 2 diabetes, Novo Nordisk, whose U.S. headquarters is based in Plainsboro, announced it will significantly ...

Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.

Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Interest surrounding glucagon-like peptide 1 agonists (GLP-1), a class of type 2 diabetes drugs that help ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and ...